Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?

Med Hypotheses. 2020 Nov;144:110202. doi: 10.1016/j.mehy.2020.110202. Epub 2020 Aug 18.

Abstract

Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.

Keywords: COVID-19; Imiquimod; SARS CoV-2; TLR7.

Publication types

  • Letter

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • COVID-19 / drug therapy*
  • COVID-19 / immunology
  • Humans
  • Imiquimod / administration & dosage
  • Imiquimod / therapeutic use*
  • Immunity, Innate / drug effects
  • Models, Immunological
  • Pandemics
  • SARS-CoV-2
  • Skin Cream
  • Toll-Like Receptor 7 / agonists*

Substances

  • Adjuvants, Immunologic
  • Antiviral Agents
  • TLR7 protein, human
  • Toll-Like Receptor 7
  • Imiquimod

Supplementary concepts

  • COVID-19 drug treatment